chronic constipation
Conditions
Interventions
The study group will take Goofice 10 mg/day starting 3 days prior to colonoscopy. The control group will not take Goofice.
Both groups will take picosulfate sodium the night before. Subsequently, on t
Sponsors
Oka Shiro
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Patients scheduled to undergo colonoscopy 2) Patients aged 18 years or older at the time of consent acquisition 3) Individuals for whom written informed consent for participation in this study can be obtained 4) Patients diagnosed by a physician with chronic constipation who meet two or more items of the ROMA-IV criteria for constipation and are in a chronic state
Exclusion criteria
Exclusion criteria: 1) Patients already taking Goofice 2) Patients with suspected gastrointestinal obstruction or intestinal obstruction 3) Patients with suspected intestinal perforation, gastric stasis, or toxic megacolon 4) Patients with inflammatory bowel disease 5) Patients who have undergone ileocecal resection or total colectomy 6) Women who are pregnant or may be pregnant, women who are breastfeeding, or women who wish to become pregnant 7) Patients with a history of hypersensitivity to Goofice, picosulfate sodium, or any component of Moviprep 8) Other patients deemed ineligible for enrollment in this study by the principal investigator or sub-investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Total volume of Moviprep and water consumed until completion of bowel preparation | — |
Secondary
| Measure | Time frame |
|---|---|
| Quality of bowel preparation Evaluation of bowel movements during the 3 days prior to the procedure and on the morning of the procedure Time required for bowel preparation and assessment of acceptability of Moviprep Evaluation of adverse events during the study period | — |
Contacts
Public ContactTakeshi Takasago
Hiroshima University Hospital
Outcome results
None listed